2006Chinese Journal of Clinical Oncology and RehabilitationRequires access

Clinical observation of oxaliplatin(L-OHP)combined with leucovorin,5-fluorouracil and hydroxycamptothecin(HCPT)for the treatment of patients with advanced colorectal cancer

Xi Yang

Open publisher page 0 citations

Abstract

Objective To observe the efficacy and toxic reaction of oxaliplatin(L-OHP)combined with hydroxycamptothecin(HCPT),leucovorin and 5-fluorouracil in the treatment of 31 patients with advanced colorectal cancer.Methods All patients were treated with L-OHP(150 mg/m~(2),ivgtt,d1)combined with leucovorin(100 mg/m~(2),ivgtt,d1 to d5),fluorouracil(500 mg/m~(2),ivgtt,d1 to d5)and HCPT(10 mg/m~(2),ivgtt,d1 to d5).The treatment was recycled every 21 days and finished after 2 recycles.Results Complete response was achieved in 2 cases,partial response in 10 cases,stable in 11cases and progression in 8 cases.The overall response rate was 38.7%.The main toxic reactions were myelosupression,nausea,vomiting(grade Ⅲ-Ⅳ 25.8%)and neuro-sensory toxicity(61.3%).Conclusion Oxaliplatin(L-OHP)combined with leucovorin,fluorouracil and hydroxycamptothecin(HCPT) regimen is effective in the treatment of advanced colorectal cancer and improves QOL.Its toxic effect is tolerable.

About this research paper

What this paper is about

Objective To observe the efficacy and toxic reaction of oxaliplatin(L-OHP)combined with hydroxycamptothecin(HCPT),leucovorin and 5-fluorouracil in the treatment of 31 patients with advanced colorectal cancer.Methods All patients were treated with L-OHP(150 mg/m~(2),ivgtt,d1)combined with leucovorin(100 mg/m~(2),ivgtt,d1 to d5),fluorouracil(500 mg/m~(2),ivgtt,d1 to d5)and HCPT(10 mg/m~(2),ivgtt,d1 to d5).The treatment was recycled every 21 days and finished after 2 recycles.Results Complete response was achieved in 2 cases,partial response in 10 cases,stable in 11cases and progression in 8 cases.The overall response rate was 38.7%.The main toxic reactions were myelosupression,nausea,vomiting(grade Ⅲ-Ⅳ 25.8%)and neuro-sensory toxicity(61.3%).Conclusion Oxaliplatin(L-OHP)combined with leucovorin,fluorouracil and hydroxycamptothecin(HCPT) regimen is effective in the treatment of advanced colorectal cancer and improves QOL.Its toxic effect is tolerable.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the efficacy and toxic reaction of oxaliplatin(L-OHP)combined with hydroxycamptothecin(HCPT),leucovorin and 5-fluorouracil in the treatment of 31 patients with advanced colorectal cancer.Methods All patients were treated with L-OHP(150 mg/m~(2),ivgtt,d1)combined with leucovorin(100 mg/m~(2),ivgtt,d1 to d5),fluorouracil(500 mg/m~(2),ivgtt,d1 to d5)and HCPT(10 mg/m~(2),ivgtt,d1 to d5).The treatment was recycled every 21 days and finished after 2 recycles.Results Complete response was achieved in 2 cases,partial response in 10 cases,stable in 11cases and progression in 8 cases.The overall response rate was 38.7%.The main toxic reactions were myelosupression,nausea,vomiting(grade Ⅲ-Ⅳ 25.8%)and neuro-sensory toxicity(61.3%).Conclusion Oxaliplatin(L-OHP)combined with leucovorin,fluorouracil and hydroxycamptothecin(HCPT) regimen is effective in the treatment of advanced colorectal cancer and improves QOL.Its toxic effect is tolerable.

Key concepts: Oxaliplatin, Medicine, Fluorouracil, Nausea, Vomiting, Regimen, Colorectal cancer, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical observation of oxaliplatin(L-OHP)combined with leucovorin,5-fluorouracil and hydroxycamptothecin(HCPT)for the treatment of patients with advanced colorectal cancer — Research Paper | ScholarLens